Risk of central line-associated bloodstream infections during COVID-19 pandemic in intensive care patients in a tertiary care centre in Saudi Arabia

This retrospective study compared central line-associated bloodstream infection (CLABSI) rates per 1 000 central line days, and overall mortality before and during the COVID-19 pandemic in adult, paediatric, and neonatal ICU patients at King Abdul-Aziz Medical City-Riyadh who had a central line and...

Full description

Saved in:
Bibliographic Details
Published in:Epidemiology and infection 2024-06, Vol.152, p.1, Article e95
Main Authors: Alshamrani, Majid M., El-Saed, Aiman, Aldayhani, Omar, Alhassan, Abdulaziz, Alhamoudi, Abdullah, Alsultan, Mohammed, Alrasheed, Mohammed, Othman, Fatmah
Format: Article
Language:English
Subjects:
COVID-19
Disease control
Disease prevention
Fatalities
Hospitalization
Hospitals
Intensive care
Morbidity
Mortality
Neonates
Original Paper
Pandemics
Patients
Pediatrics
Severe acute respiratory syndrome coronavirus 2
Staphylococcus infections
Surveillance
Ventilators
Viral diseases
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This retrospective study compared central line-associated bloodstream infection (CLABSI) rates per 1 000 central line days, and overall mortality before and during the COVID-19 pandemic in adult, paediatric, and neonatal ICU patients at King Abdul-Aziz Medical City-Riyadh who had a central line and were diagnosed with CLABSI according to the National Healthcare Safety Network standard definition. The study spanned between January 2018 and December 2019 (pre-pandemic), and January 2020 and December 2021 (pandemic). SARS-CoV-2 was confirmed by positive RT-PCR testing. The study included 156 CLABSI events and 46 406 central line days; 52 and 22 447 (respectively) in pre-pandemic, and 104 and 23 959 (respectively) during the pandemic. CLABSI rates increased by 2.02 per 1 000 central line days during the pandemic period (from 2.32 to 4.34, p 
ISSN:0950-2688
1469-4409
1469-4409
DOI:10.1017/S0950268824000736